Stock info Gilead Sciences | Filter Basic-Info
Stock: Gilead Sciences (US Tech), ISIN: US3755581036
| Last Price | 147.68 | Max Price | 155.80 |
| Min Price | 110.56 | 1 Year return | 89.28 |
| Sector | Health Care | Subsector | Biotechnology |
| Annual report 2020 |
Loading...
Contact info:Street: Foster City, CA 94404Zip Code: CA 94404City: Foster CityCountry: USAPhone: (650) 5743000Email: investor_relations@gilead.comWebsite: www.gilead.comCEO: John C. MartinCFO: Robin L. Washington
Sector Review Gilead Sciences
Loading...
| Year | Turnover | Total sector | Market share |
|---|---|---|---|
| 2019 | 20,026 | 136,070 | 14.72 % |
| 2020 | 20,215 | 153,065 | 13.21 % |
| 2021 | 24,019 | 227,669 | 10.55 % |
| 2022 | 25,491 | 260,393 | 9.79 % |
| 2023 | 24,571 | 215,054 | 11.43 % |
Advice Gilead Sciences
News Gilead Sciences
Gilead Sciences in top American dividend stocks
00For this year the analysts expect a dividend of 3.13 USD per share. Thus the dividend yield equals 4.67 percent. The average dividend yield of the biotech companies equals an attractive 3.55 percent. Historical dividend returns Gilead Sciences Tomorrowthe...
FDA puts partial clinical hold on Gilead's magrolimab + azacitidine studies
Gilead Sciences (NASDAQ:GILD) announces that the FDA has placed a partial clinical hold on studies evaluating the combination of magrolimab plus azacitidine due to an apparent imbalance in suspected unexpected serious adverse reactions (SUSARs) between study...
Gilead and Merck ink collaboration agreement for Keytruda/Trodelvy breast cancer study
Gilead Sciences (NASDAQ:GILD) has entered into a clinical trial collaboration and supply agreement with Merck KGaA (NYSE:MRK) to evaluate the efficacy of Trodelvy in combination with Keytruda as a first-line treatment for certain patients with triple-negative...
Gilead and Novo Nordisk expand collaboration in NASH therapeutics
Gilead Sciences (NASDAQ:GILD) and Novo Nordisk (NYSE:NVO) have announced an expansion of their clinical collaboration in non-alcoholic steatohepatitis ('NASH").
The two companies have agreed to conduct a Phase 2b study to investigate the safety and efficacy...
Gilead Sciences now in top highest dividend yields in America
Investors in Gilead Sciences can expect a huge dividend payment. Based on the recent analysts' consensus the stock now has one of the highest dividend returns of the American market. Per share the analysts anticipate on a dividend of 2,7 USD per share. The dividend...
Annual reports Gilead Sciences
| 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|
Profile Gilead Sciences
No Records Found
Results Gilead Sciences
| Results |
2021
|
2022
|
2023
|
2024
|
2025
|
|---|---|---|---|---|---|
| Revenue |
|
|
|
|
|
| Costs |
|
|
|
|
|
| Profit |
|
|
|
|
|
| Margin of profit |
|
|
|
|
|
| ROI |
|
|
|
|
|
Balance Gilead Sciences
| Balance |
2021
|
2022
|
2023
|
2024
|
2025
|
|---|---|---|---|---|---|
| Equity |
|
|
|
|
|
| Debt |
|
|
|
|
|
| Total assets |
|
|
|
|
|
| Solvency |
|
|
|
|
|
| Cash |
|
|
|
|
|
| Cashflow |
|
|
|
|
|
| Employees |
|
|
|
|
|
| Revenue per employee |
|
|
|
|
|
| Cashflow / Debt |
|
|
|
|
|
Details Gilead Sciences
| Details |
2016
|
2017
|
2018
|
2019
|
2020
|
|---|---|---|---|---|---|
| Price |
71.61
|
71.64
|
62.55
|
64.98
|
58.26
|
| Eps |
9.46
|
2.92
|
3.64
|
3.76
|
0.08
|
| Price/earnings-ratio |
7.57
|
24.53
|
17.18
|
17.28
|
1846.00
|
| Dividend |
1.75
|
1.73
|
1.99
|
2.25
|
2.23
|
| Dividend % |
2.44 %
|
2.41 %
|
3.18 %
|
3.46 %
|
1.51 %
|
| Payout % |
0.18
|
0.59
|
0.55
|
0.60
|
27.88
|
| Book value |
13.75
|
13.03
|
14.55
|
15.87
|
11.89
|
| Market to book |
0.19
|
0.18
|
0.23
|
0.24
|
0.08
|
| Cashflow per stock |
12.41
|
7.58
|
5.71
|
6.44
|
5.33
|
| Stocks |
1,307
|
1,308
|
1,282
|
1,266
|
1,254
|
| Market Cap |
93.594.27
|
93.705.12
|
80.189.10
|
82.264.68
|
185.190.72
|
Dividend Gilead Sciences
Price info Gilead Sciences
|
Date
|
Price
|
|---|---|
|
17 Sep 2026
|
147.68
|
|
15 Sep 2026
|
146.41
|
|
14 Sep 2026
|
143.72
|
|
28 Aug 2026
|
148.86
|
|
11 Aug 2026
|
133.06
|
|
07 Aug 2026
|
130.86
|
|
06 Aug 2026
|
131.76
|
|
28 Jul 2026
|
130.52
|
|
14 Jul 2026
|
131.40
|
|
09 Jul 2026
|
134.84
|
|
08 Jul 2026
|
135.82
|
|
07 Jul 2026
|
136.36
|
|
06 Jul 2026
|
129.61
|
|
02 Jul 2026
|
131.27
|
|
01 Jul 2026
|
125.97
|
|
30 Jun 2026
|
126.34
|
|
29 Jun 2026
|
126.33
|
|
26 Jun 2026
|
127.88
|
|
25 Jun 2026
|
123.84
|
|
24 Jun 2026
|
125.16
|
|
23 Jun 2026
|
125.05
|
|
22 Jun 2026
|
124.87
|
|
18 Jun 2026
|
123.76
|
|
17 Jun 2026
|
125.45
|
|
16 Jun 2026
|
127.23
|
|
15 Jun 2026
|
124.30
|
|
12 Jun 2026
|
125.59
|
|
11 Jun 2026
|
125.87
|
|
10 Jun 2026
|
121.48
|
|
09 Jun 2026
|
125.50
|
| About us | Network | Partners |
| Fpgroup.nlinfo@analist.nlRSS feedContactIntellectual Property Photos |
Analist.nlLinksISIN
|
MorningstarPrudena.comAAII.comNASDAQvwd GroupEuronextBATS Chi-x |
©2026 Scanaktier. Alla rättigheter reserverade
Developed and maintained by 